Clinical Trial Update: A Safety Study to Investigate the Skin Sensitization Potential of MFC51123 [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study evaluated the skin sensitization potential of the compound MFC51123.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• MFC51123 (MFC51123)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pain | Phase 1 | Status: COMPLETED